Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.51 |
| ▸ | TUBB | P07437 | 1/20 | 0.51 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.51 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.51 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.51 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.51 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.51 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.51 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.51 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.51 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.51 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.51 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.51 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.51 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548433 | 0.83 | NPC1 (0.58) | MAPTALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12036831 | 0.81 | TUBB4A (0.36) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL16400769 | 0.81 | TUBB4A (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL934205 | 0.80 | NQO1 (0.48) | ALDH1A1ERN1CA12CA1CA2 | |
| SCHEMBL31371078 | 0.80 | FDPS (0.40) | MAPTALDH1A1HPGD | |
| SCHEMBL3721591 | 0.79 | TUBB4A (0.43) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18951811 | 0.79 | TUBB4A (0.51) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL18851550 | 0.79 | TUBB4A (0.56) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL102267 | 0.79 | ALDH1A3 (0.53) | ALDH1A1ERN1KCNJ1GLASMN1; SMN2 | |
| SCHEMBL904471 | 0.78 | KCNJ1 (0.38) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 287 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| CN-116903631-B | Near-infrared double-lock fluorescent probe CO-activated by CO and viscosity, and synthesis method and application thereof | 中南大学深圳研究院 | 2025-05-27 | — | — | CN | claimed |
| CN-119874677-A | Imidazolidinone compound, porous organic polymer gel, and preparation methods and applications thereof | 四川大学 | 2025-04-25 | — | — | CN | claimed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-116903631-A | Near-infrared double-lock fluorescent probe CO-activated by CO and viscosity, and synthesis method and application thereof | 中南大学深圳研究院 | 2023-10-20 | — | — | CN | claimed |
| CN-110423234-B | Thiosemicarbazone derivative containing indole fragment and preparation method and application thereof | 郑州大学 | 2020-06-30 | — | — | CN | claimed |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| US-12583855-B2 | RET selective inhibitor, preparation method therefor and use thereof | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2026-03-24 | — | — | US | disclosed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | Bugworks Research, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-12545683-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | 3+2 PHARMA, LLC (US) | 2026-02-10 | — | — | US | disclosed |
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | KAMARI PHARMA LTD. (IL) | 2025-10-07 | — | — | US | disclosed |
| WO-2007120729-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007096763-A2 | MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES | PFIZER LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096763-A2 | MELANOCORTIN TYPE 4 RECEPTOR AGONIST PIPERIDINOYLPYRROLIDINES | PFIZER LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1700856-A1 | THIAZOLE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-6677456-B2 | AS ANTITUMOR COMPOUND; CAN BE ORALLY ADMINISTERED | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20020143178-A1 | Pentacyclic taxan compound | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435061-B2 | Compounds and compositions for use in treating skin disorders | RDX, HAX1, F12 | TUBB4A 2969/4885TUBB 3990/4885TUBA3C 3433/4885 |
| US-12583855-B2 | RET selective inhibitor, preparation method therefor and use thereof | RET, ROR1, TMPRSS11D | TUBB4A 3504/4885TUBB 2933/4885TUBA3C 3656/4885 |
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | IKZF1, IKZF2, BCL6 | TUBB4A 2950/4885TUBB 1970/4885TUBA3C 1079/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | TUBB4A 3091/4885TUBB 2419/4885TUBA3C 2397/4885 |
| US-12545683-B2 | CBP/catenin signaling pathway inhibitors and uses thereof | CREBBP, CREB1, CTNNB1 | TUBB4A 1680/4885TUBB 1328/4885TUBA3C 3189/4885 |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | ADORA1, ADORA3, ADORA2A | TUBB4A 2491/4885TUBB 2297/4885TUBA3C 1441/4885 |
| US-20070105919-A1 | adenosine A2A receptor antagonists; N-[4-(2-Furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxamide; treatment of Parkinson's disease, Alzheimer's disease, progressive supranuclear palsy, AIDS encephalopathy, nerve system disorders | ADORA2A, ADORA3, ADORA1 | TUBB4A 2251/4885TUBB 2411/4885TUBA3C 2282/4885 |
| US-20020143178-A1 | Pentacyclic taxan compound | TUBB6, TUBB1, TUBA1A | TUBB4A 17/4885TUBB 10/4885TUBA3C 42/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | TUBB4A 4270/4885TUBB 3834/4885TUBA3C 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.